CAMBRIDGE, Mass.– Valink Therapeutics, a private biotechnology company developing next-generation therapeutics with a focus on bispecific antibody-drug conjugates (bsADCs) and complementary modalities, and Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from “Idea to IND” (I to I®), on Tuesday announced the formation of a strategic biologics discovery alliance.
The collaboration, branded “Biology to Bispecific” (B2B)™, brings together the companies’ complementary platforms and expertise to accelerate the development of innovative bispecific antibodies and bispecific ADCs. Initially focused on bsADCs for solid tumors, the alliance is expected to expand Valink’s internal therapeutic pipeline and support future co-development and licensing opportunities.
Under the terms of the agreement, Valink will combine its LiliumX™ discovery platform with Nona’s Harbour Mice® fully human antibody technologies, including its heavy chain-only antibodies (HCAbs), to generate and screen thousands of novel drug candidates. Nona Biosciences has previously supported more than 300 drug discovery programs across multiple therapeutic areas, building an extensive antibody repertoire that serves as a foundation for complex biologics development.
Valink’s LiliumX technology enables high-throughput generation and functional screening of complex drug candidates derived from antibody fragments. When paired with Nona’s diverse antibody library, the platform is designed to enable deeper exploration of complex biologics, uncovering novel targeting strategies and target-pair synergies consistent with Valink’s V-gate™ approach.
“We are thrilled to form this discovery alliance with Nona – it constitutes a logical and natural expansion of our discovery platform,” said Dr Arne Scheu, Chief Executive Officer of Valink Therapeutics. “With Nona, we have found an excellent partner, supercharging our ability to build transformative drugs with which we can meaningfully impact patients’ lives.”
Dr. Di Hong, Chief Executive Officer of Nona Biosciences, said the partnership is expected to accelerate innovation across multiple therapeutic areas. “We are excited to collaborate with Valink to accelerate the creation of innovative biotherapeutics. By uniting our industry-leading antibody technology platforms and extensive experiences with Valink’s LiliumX discovery engine, we aim to accelerate the pace of bispecific antibody and bsADC discovery and development, ultimately delivering transformative therapies to patients in oncology and beyond.”
